Private equity investors remain bullish on hospice with no signs of slowing down. However, with a number of high-profile transactions completed or in the works during 2020 and 2021, the number of hospices of scale that are likely to come to market is dwindling. During the next few years, PE firms will likely fix their eyes on smaller operations in what remains a highly fragmented industry.
The medical office building market is a niche one, but has attracted increasing interest from investors over the past decade. Investors see medical office buildings, which typically include ASCs, physician offices and screening centers, as desirable assets because of their resilience during market shifts, high occupancy rates and positive outlook. Largely because of the COVID-19 pandemic, medical office building sales volume declined 12.2 percent year over year to $11.1 billion in 2020, but the drop off was far less than other commercial real estate sectors, according to a report from Colliers, a real estate investment management company. But in the coming years, in line with the country’s aging population, the number of medical office buildings is expected to boom.
Innovation remains the name of the game in the healthcare industry. More than a year after the start of the Covid-19 pandemic, investment in technology and innovative devices and procedures continues to drive advances in the treatment and prevention of diseases and the delivery of care. It is also changing how hospital systems operate and helping practitioners and investors alike connect the dots between more inclusive growth, better healthcare outcomes and attractive investment opportunities.
Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector, announced today the closing of its second fund, Amulet Capital Partners II (the “Fund”). The Fund, executed as a mostly virtual process, was oversubscribed and closed with in excess of $650 million in capital commitments, exceeding the Fund’s target of $500 million. The firm’s thematic approach to healthcare investing, focusing on complex and advantaged situations as well as a consistent approach to driving value post-acquisition, attracted strong support from new and existing investors.
Private equity acquisitions of Dental companies have accelerated in recent years as PE firms employ an industry roll-up strategy in this traditionally fragmented space. The Private Equity Info Research Database shows 175 platform portfolio companies held by private equity firms in the Dental space. These companies are collectively held by 159 private equity firms. The following is a brief overview of private equity-backed Dental Support Organizations, Dental Products Manufacturing, Dental Software and Dental Laboratories.
The Centers for Medicare and Medicaid Services will turn a skeptical eye toward venture capital and private equity investments in healthcare and demand greater transparency, a key agency official said Wednesday. Officials worry patients won’t get the care they need if investors are only in healthcare to collect government money, Pauline Lapin, director of the Center for Medicaid and Medicaid Innovation’s Seamless Care Models Group, said during the Policies, Techies & VCs conference on Wednesday.
With nearly 30 portfolio companies, many in states like Alabama, Texas, Georgia and Florida, Shore Capital Partners Managing Partner Justin Ishbia knows the Southeast — and he knows where he’s putting his money. “We have a huge Southeast focus … but we believe Nashville to be the capital of the Southeast,” Ishbia said. Shore has plenty of money to invest, having recently closed three new funds worth more than $700 million, including a more than $360 million health care fund, Ishbia said. Part of that fund, which is Shore’s fourth dedicated to health care, will go toward launching a new Nashville health care company in the coming weeks.
In this edition of “Lessons from the C-suite,” featuring Advisory Board President Eric Larsen’s conversations with the most influential leaders in health care, Robb Vorhoff, General Atlantic’s Managing Director and Global Head of Healthcare, shares with Eric some of his overarching healthcare investment hypotheses, the origin stories around Oak Street Health and Alignment Healthcare, and the type of business he would start if given the chance.
Economic activity in the healthcare market has translated into record venture fundraising, an acceleration in private investments in biopharma and healthtech and elevated IPO activity – ultimately changing the face of healthcare.
Since 1980 and Professor Martin J. Cline’s first attempt at Gene Therapy biomedicine has experienced tremendous progress, particularly in the field of cell and gene therapy. The emergence of this field means hope for many around the world for a cure to their diseases rather than treat symptoms. How do the private equity and special-purpose acquisition companies (SPACs) fit into this picture?
We publish a Daily Note that aggregates M&A activity, notable developments, regulatory changes, and conferences we deem to be of interest to our partners. It is a quick afternoon read and an easy way to keep your finger on the pulse of the healthcare space. Please fill in your name and email address below if you wish to subscribe.